AOD-9604 — Research Dossier
Evidence grading
Structure
hGH(176–191) + Tyr
16-residue C-terminal hGH fragment with N-terminal tyrosine
Largest trial
Phase IIb
~500+ subjects, multi-centre randomised controlled trial (2007)
Primary endpoint
Not met (2007)
Weight loss not clinically meaningful versus placebo
IGF-1 effect
None
Does not raise IGF-1 or affect glucose or insulin metabolism
AOD-9604 completed a full pharmaceutical development programme through Phase IIb and produced a clear negative efficacy result alongside one of the cleanest safety datasets in the peptide research category — it is best understood by what the trials actually found, rather than the mechanism alone.
AOD-9604 ("Anti-Obesity Drug 9604") corresponds to amino acids 176–191 of human growth hormone — the C-terminal segment carrying GH's lipolytic activity — with a tyrosine residue added at the N-terminus for stability. It was developed by Metabolic Pharmaceuticals Ltd (Melbourne) from structure-function work at Monash University led by Frank Ng, which showed that GH's fat-metabolising activity could be reproduced by this fragment without the growth-promoting, insulin-antagonist, or IGF-1-elevating activities residing elsewhere in the molecule.
It is unusual among research peptides in having completed a full pharmaceutical development programme through Phase IIb, producing both a clear negative efficacy result and a reassuring safety dataset across six human trials and over 900 participants.
“The Phase IIb trial failed to meet its primary weight-loss endpoint — observed weight loss was modest and not clinically meaningful by regulatory standards — while the safety dataset across 900+ participants showed no IGF-1 elevation, no glucose disturbance, and no notable adverse signal.”
— Metabolic Pharmaceuticals Ltd, Phase IIb multi-centre RCT (2007)
Mechanism
AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue. Critically, it does not activate the GH receptor in the conventional manner and does not raise IGF-1 or affect glucose or insulin metabolism. Its fat-metabolism effects are considered receptor-independent and peripheral, distinguishing it mechanistically from both full-length GH and the centrally acting GLP-1 agonists.
The absence of systemic GH-receptor activation — no IGF-1 elevation, no insulin resistance, no growth-promoting effect — was the mechanistic rationale for developing it as a safer alternative to GH for fat-loss indications. This separation of lipolytic from anabolic GH activity remains the key mechanistic insight, even though clinical efficacy did not follow.
Clinical evidence base
Preclinical (positive signal)
Heffernan et al. (2001) demonstrated AOD-9604 stimulated lipolysis in obese and lean mice without altering IGF-1 levels or insulin sensitivity, validating the mechanism-of-separation concept and supporting progression to human trials.
Phase IIa (positive signal)
Early-phase human studies showed dose-dependent effects on lipolysis in obese subjects, providing sufficient signal to advance to a larger randomised trial.
Phase IIb — the decisive result
A multi-centre, randomised, double-blind, placebo-controlled trial conducted by Metabolic Pharmaceuticals (2007) enrolled several hundred obese subjects over approximately 12–24 weeks. The trial failed to meet its primary endpoint: observed weight loss beyond placebo was modest — on the order of 1–2 kg — and not clinically meaningful by regulatory standards. Development as an obesity therapeutic was discontinued. Safety was reassuring across all six human trials: no IGF-1 elevation, no glucose disturbance, no notable adverse signal. Metabolic Pharmaceuticals later explored cartilage-repair and osteoarthritis applications with mixed published results.
Regulatory status
AOD-9604 holds no approval from any major regulator. The FDA placed it on the Category 2 bulk-substances list, meaning it cannot be compounded under 503A or 503B pathways. Australia's TGA granted it food-ingredient status in 2012 — a safety classification, not a therapeutic approval. Material supplied for laboratory work is research-use-only in the UK.
Evidence grade: Phase IIb — efficacy not demonstrated. The mechanism is well-characterised and the safety profile is clean, but the pivotal human trial did not show clinically meaningful weight loss.
See also
References
- 1
Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice Endocrinology / Int J Obes 2001.
- 2
Ng FM, et al. Structure-function studies of the lipolytic domain of human growth hormone (hGH 176–191) Monash University endocrinology programme 1997.
- 3
Metabolic Pharmaceuticals Ltd Phase IIb multi-centre randomised placebo-controlled obesity trial of AOD-9604 Clinical programme (multi-centre RCT) 2007.
- 4
US FDA AOD-9604 — Category 2 bulk drug substance determination FDA Bulk Drug Substance Decisions 2016.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
